Gastrointestinal Cancers

After one woman’s father received a terminal stomach cancer diagnosis, she turned to Debbie’s Dream Foundation: Curing Stomach Cancer for information and guidance.

November is Stomach Cancer Awareness Month. Here's a round up of the latest news and updates in this disease space.

Best-selling author V. Gilbert Beers surprises doctors and proves “age is just a number.”

After turning to Debbie’s Dream, one woman shares how receiving support from fellow caregivers of loved ones with stomach cancer led to her to call on home health nurses throughout her husband’s journey.

A nearly 10-year stomach cancer survivor works with Debbie’s Dream Foundation to raise disease awareness and raise money for a cure.

Patients with gastrointestinal cancers should be aware of specific side effects that might arise — and ways to prevent or ease them.

An oncology dietitian offered advice on how to improve appetite and eat healthy before, during and after treatment for gastrointestinal cancers.

Cancer can indeed be a numbers game, but I am no way just a statistic — no one is. This journey has given me a newfound perspective on life and the amazing work that Stand Up To Cancer does.

The Food and Drug Administration approved Kanjinti, a biosimilar to the US-licensed Herceptin, marking it the fifth of its kind.

From today’s top entertainers to racial disparities in access to pain treatment, here’s what is making headlines in the cancer space this week.

Emerging facts about the genetics that drive gastric cancer are leading to new treatments for the disease.

Overall survival in metastatic gas­tric or gastroesophageal junction cancer improved significantly in patients who received the oral combination chemo­therapy Lonsurf regardless of whether they’d had a gastrectomy.

Nearly half of patients with a particular type of cholangiocarcinoma responded to a combination of two targeted drugs — Tafinlar (dabrafenib) and Mekinist (trametinib), which together inhibit the growth-signaling proteins BRAF and MEK in patients with different types of rare cancers that carry the BRAF V600E gene mutation.

There’s a greater responsibility than ever to understand gastric cancer, its causes and its treatments.

The Food and Drug Administration approved Lonsurf (TAS-102; trifluridine/tipiracil) for adult patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.

The Food and Drug Administration (FDA) has granted a priority review to a supplemental new drug application for Lonsurf (TAS-102; trifluridine/tipiracil) for use in previously treated patients with advanced or metastatic gastric adenocarcinoma, including cancer of the gastroesophageal junction.

The Food and Drug Administration (FDA) approved an expanded age indication for GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant), according to Merck, the manufacturer of the HPV vaccine.

Immunotherapy pioneers James P. Allison and Dr. Tasuku Honjo have won the 2018 Nobel Prize in Physiology or Medicine for their research that eventually led to the use of immune checkpoint inhibitors to treat cancer.

Research continues to drive the oncology field.

A recent study found that socioeconomic status can play a role in survival for patients with anal cancer.

While having a career as a flight attendant allows individuals to travel the globe, exposure to carcinogens and frequent disruptions in circadian rhythms may increase cancer prevalence in these individuals, according to recent research published in the journal Environmental Health.

Treatment of HIV has drastically improved since the 1980s, but many of these individuals are still facing barriers to proper cancer care.

But just what information is most useful to patients with NETs, and where are the gaps in the educational and supportive resources to which they have access? A study – presented at the Gastrointestinal Cancers Symposium on Jan. 19, in San Francisco – explored just that.

Keytruda (pembrolizumab) was granted FDA approval for the treatment of patients with recurrent or advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received two or more lines of chemotherapy and are PD-L1-positive.